Pregled po CROSBI profilu: IVAN KREČAK (CROSBI Profil: 40410)
Pronađeno 74 radova
-
1.Higher JAK2 V617F mutant allele burden in patients with chronic myeloproliferative neoplasms is associated with a higher prevalence of chronic kidney disease and unfavorable dynamics of kidney function over time // Annals of Hematology (2023) doi:10.1007/s00277-023-05305-3 (međunarodna recenzija, online first)
-
2.Clinical presentation, treatment patterns, and outcomes of pulmonary embolism in patients with chronic myeloproliferative neoplasms // Thrombosis Research (2023) doi:10.1016/j.thromres.2023.03.004 (međunarodna recenzija, online first)
-
3.High plateletcrit may be associated with thrombotic risk in polycythemia vera // International Journal of Laboratory Hematology (2023) doi:10.1111/ijlh.14073 (međunarodna recenzija, online first)
-
4.Pulmonary embolism, is it healthy to be volume expanded? // European Journal of Internal Medicine (2023) doi:10.1016/j.ejim.2023.05.010 (međunarodna recenzija, online first)
-
5.Specific symptom burden in patients with chronic myeloproliferative neoplasms and chronic kidney disease // Annals of Hematology (2023) doi:10.1007/s00277-023-05296-1 (međunarodna recenzija, online first)
-
6.Polypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative Neoplasms // Biomedicines, 11 (2023), 5; 1301, 16 doi:10.3390/biomedicines11051301 (međunarodna recenzija, članak, znanstveni)
-
7.Chronic kidney disease and thrombotic risk in patients with chronic myeloproliferative neoplasms // Journal of Thrombosis and Thrombolysis, 55 (2023), 4; 760-761 doi:10.1007/s11239-023-02779-w (međunarodna recenzija, članak, znanstveni)
-
8.Hematocrit to hemoglobin ratio (HHR) may improve prognostication in patients with pulmonary embolism // Scandinavian Journal of Clinical and Laboratory Investigation, 83 (2023), 3; 200-203 doi:10.1080/00365513.2023.2191334 (međunarodna recenzija, članak, znanstveni)
-
9.Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis // Biochemia Medica, 33 (2023), 2; 020901, 8 doi:10.11613/bm.2023.020901 (međunarodna recenzija, članak, znanstveni)
-
10.Palpable spleen size is differently prognostic in primary and secondary myelofibrosis // Leukemia & lymphoma, 64 (2023), 4; 893-896 doi:10.1080/10428194.2023.2179360 (međunarodna recenzija, pismo, znanstveni)
-
11.Can we use platelet-to-lymphocyte ratio (PLR) to differentiate JAK2-unmutated erythrocytosis from polycythemia vera? // European journal of internal medicine, 108 (2023), 120-121 doi:10.1016/j.ejim.2022.09.023 (međunarodna recenzija, pismo, znanstveni)
-
12.Understanding and modifying thrombotic risk in patients with myeloproliferative neoplasms // Journal of Cardiology, 81 (2022), 6; 586-586 doi:10.1016/j.jjcc.2022.12.009 (međunarodna recenzija, pismo uredniku, znanstveni)
-
13.Higher estimated plasma volume status may be associated with an inferior survival in patients with pulmonary embolism // International journal of laboratory hematology, 45 (2022), 2; e32-e35 doi:10.1111/ijlh.13982 (međunarodna recenzija, pismo uredniku, znanstveni)
-
14.Chronic Kidney Disease has a Higher Prevalence in Polycythemia Vera than in Secondary Polycythemia, a Matched Case–Control Analysis // Indian Journal of Hematology and Blood Transfusion (2022) doi:10.1007/s12288-022-01624-z (međunarodna recenzija, online first)
-
15.P-206 Association between primary tumor site of colorectal cancer and RAS/BRAF mutational status with venous thromboembolism: A retrospective- prospective cohort study from 3 Croatian oncology centers // Abstract Book of the ESMO 24th World Congress on Gastrointestinal Cancer 2022
Barcelona, Španjolska: Elsevier BV, 2022. str. S322-S323 doi:10.1016/j.annonc.2022.04.296 (poster, međunarodna recenzija, sažetak, stručni) -
16.Sistemska mastocitoza u Republici Hrvatskoj // Liječnički vjesnik, 144 (2022), 9-10; 306-313 doi:10.26800/lv-144-9-10-3 (domaća recenzija, članak, znanstveni)
-
17.Estimated Plasma Volume Status in Patients With Primary Myelofibrosis and Associated Thrombotic and Mortality Risks // Clinical Lymphoma, Myeloma & Leukemia 22 Suppl. 2: Society of Hematologic Oncology Tenth Annual Meeting
Houston (TX), Sjedinjene Američke Države, 2022. str. S341-S342 doi:10.1016/s2152-2650(22)01467-7 (predavanje, međunarodna recenzija, sažetak, znanstveni) -
18.Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis // Leukemia research, 119 (2022), 106905, 4 doi:10.1016/j.leukres.2022.106905 (međunarodna recenzija, kratko priopcenje, znanstveni)
-
19.Comparison of IMPROVE, modified IMPROVE, IMPROVEDD, Padua and CHA2DS2-VASC risk scores for venous and arterial thrombotic events prediction in hospitalized COVID-19 patients // Thrombosis research, 214 (2022), 37-39 doi:10.1016/j.thromres.2022.04.009 (međunarodna recenzija, članak, znanstveni)
-
20.Gradual increase in red cell distribution width is similarly prognostic for in-hospital mortality in both anemic and non-anemic COVID-19 patients // Journal of medical virology, 94 (2022), 8; 3509-3511 doi:10.1002/jmv.27785 (međunarodna recenzija, pismo, znanstveni)
-
21.Scurvy // Acta dermatovenerologica Croatica, 30 (2022), 1; 59-60 (međunarodna recenzija, pismo, znanstveni)
-
22.Serum osmolarity in polycythemia vera and its clinical associations // International journal of laboratory hematology, Online ahead of print. (2022), 1-4 doi:10.1111/ijlh.13844 (međunarodna recenzija, pismo, znanstveni)
-
23.Concomitant multiple sclerosis and polycythemia vera successfully treated with glatiramer acetate // Annals of hematology, 101 (2022), 8; 1885-1886 doi:10.1007/s00277-022-04839-2 (međunarodna recenzija, prikaz, znanstveni)
-
24.Persistent fever, bloody diarrhea, and skin necrosis in a young female // European journal of internal medicine, 101 (2022), 108-109 doi:10.1016/j.ejim.2022.05.008 (međunarodna recenzija, prikaz, znanstveni)
-
25.High platelet-to-lymphocyte ratio may differentiate polycythemia vera from secondary polycythemia // Wiener klinische Wochenschrift, 134 (2022), 11-12; 483-486 doi:10.1007/s00508-022-02027-w (međunarodna recenzija, članak, znanstveni)
-
26.Platelet-to-lymphocyte ratio and accelerated atherosclerosis in essential thrombocythemia and polycythemia vera // Nutrition metabolism and cardiovascular diseases, 32 (2022), 8; 2010-2011 doi:10.1016/j.numecd.2022.05.001 (međunarodna recenzija, pismo uredniku, stručni)
-
27.Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia // Current Hematologic Malignancy Reports, 17 (2022), 5; 155-169 doi:10.1007/s11899-022-00670-8 (međunarodna recenzija, pregledni rad, stručni)
-
28.Renal disease associated with chronic myeloproliferative neoplasms // Expert review of hematology, 15 (2022), 2; 93-96 doi:10.1080/17474086.2022.2039117 (međunarodna recenzija, pregledni rad, znanstveni)
-
29.The Prevalence of Simple Kidney Cysts in Polycythemia Vera and Its Clinical Associations // Indian Journal of Hematology and Blood Transfusion, 38 (2022), 2; 429-431 doi:10.1007/s12288-021-01515-9 (međunarodna recenzija, pismo uredniku, stručni)
-
30.Darier's sign // European Journal of Internal Medicine, 97 (2022), 97-98 doi:10.1016/j.ejim.2022.01.004 (međunarodna recenzija, prikaz, znanstveni)
-
31.Thrombotic risk in secondary polycythemia resembles low-risk polycythemia vera and increases in specific subsets of patients // Thrombosis Research, 209 (2022), 47-50 doi:10.1016/j.thromres.2021.11.025 (međunarodna recenzija, pismo uredniku, stručni)
-
32.Smjernice za dijagnostiku i liječenje policitemije vere // Bilten Krohema, 13 (2021), 1; 32-35 (domaća recenzija, pregledni rad, znanstveni)
-
33.Smjernice za liječenje bolesnika s novodijagnosticiranom akutnom mijeloičnom leukemijom koji nisu podobni za liječenje intenzivnim oblicima liječenja // Bilten Krohema, 13 (2021), 2; 30-31 (podatak o recenziji nije dostupan, ostalo, stručni)
-
34.COVID-19 u hematoloških bolesnika – analiza Krohema (5/2021) // Bilten Krohema, 13 (2021), 2; 3-4 (podatak o recenziji nije dostupan, osvrt, ostalo)
-
35.Efficacy and tolerability of trifluridine/tipiracil in patients with refractory metastatic colorectal cancer at the general hospital of Šibenik-Knin country // Libri Oncologici : Croatian Journal of Oncology, 49 (2021), 2-3; 76-79 (domaća recenzija, članak, znanstveni)
-
36.THE CONTROLLING NUTRITIONAL STATUS (CONUT) SCORE MIGHT PREDICT SURVIVAL IN MAINTENANCE HEMODIALYSIS PATIENTS // Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske, 75 (2021), 2; 123-130 (domaća recenzija, članak, znanstveni)
-
37.Purine analogues increase the risk of lethal and/or prolonged COVID19 while obinutuzumab increases the risk of prolonged but not lethal infection in patients treated for lymphoid malignancies - a study of Krohem, the Croatian group for hematologic diseases // Blood, 138 (2021), Suppl 1
Atlanta (GA), Sjedinjene Američke Države, 2021. str. 3553-3553 doi:10.1182/blood-2021-149613 (poster, međunarodna recenzija, sažetak, znanstveni) -
38.Concomitant autoimmune hemolytic anemia and pure red cell aplasia in a patient with chronic lymphocytic leukemia successfully treated with ibrutinib // Annals of Hematology, 100 (2021), 11; 2861-2862 doi:10.1007/s00277-021-04570-4 (međunarodna recenzija, pismo uredniku, znanstveni)
-
39.Paraneoplastic aortitis in a patient with relapsed multiple myeloma successfully treated with daratumumab, bortezomib and dexamethasone // Annals of Hematology, 100 (2021), 6; 1623-1624 doi:10.1007/s00277-020-04369-9 (međunarodna recenzija, prikaz, znanstveni)
-
40.Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism // Blood Cancer Journal, 11 (2021), 189, 5 doi:10.1038/s41408-021-00585-2 (međunarodna recenzija, pismo uredniku, znanstveni)
-
41.No impact of the increased number of cardiovascular risk factors on thrombosis and survival in polycythemia vera // Oncology research and treatment, 44 (2021), 4; 201-203 doi:10.1159/000514347 (međunarodna recenzija, pismo uredniku, stručni)
-
42.Cryptic brain abscess ‐ do not forget hereditary hemorrhagic teleangiectasia! // American Journal of Hematology, 96 (2021), 5; 640-642 doi:10.1002/ajh.26111 (međunarodna recenzija, prikaz, znanstveni)
-
43.Low-density lipoprotein (LDL) and the risk of thrombotic events in essential thrombocythemia and polycythemia vera // Annals of hematology, 100 (2021), 5; 1335-1336 doi:10.1007/s00277-021-04431-0 (međunarodna recenzija, pismo uredniku, stručni)
-
44.Modifying the effects of cytoreductive drugs on kidney function in myeloproliferative neoplasms // Pharmacology, 106 (2021), 7-8; 451-452 doi:10.1159/000516894 (međunarodna recenzija, komentar, stručni)
-
45.Autoimmune disorders and the risk of thrombotic events in polycythaemia vera // Leukemia Research, 110 (2021), 34274855, 3 doi:10.1016/j.leukres.2021.106667 (međunarodna recenzija, pismo uredniku, znanstveni)
-
46.Neutrophil‐to‐lymphocyte and platelet‐to‐lymphocyte ratios as prognostic biomarkers in polycythemia vera // International journal of laboratory hematology, 44 (2021), 4; e145-e148 doi:10.1111/ijlh.13786 (međunarodna recenzija, pismo uredniku, znanstveni)
-
47.Hematocrit to hemoglobin ratio as a prognostic marker in polycythemia vera // Wiener klinische Wochenschrift, 134 (2021), 3-4; 110-117 doi:10.1007/s00508-021-01967-z (međunarodna recenzija, članak, znanstveni)
-
48.Beneficial effect of ACE inhibitors on kidney function in polycythemia vera // Wiener klinische Wochenschrift, 133 (2021), 15-16; 808-815 doi:10.1007/s00508-021-01812-3 (međunarodna recenzija, članak, znanstveni)
-
49.Estimating plasma volume using the Strauss‐ derived formula may improve prognostication in polycythemia vera // International Journal of Laboratory Hematology, Online ahead of print (2021), https://doi.org/10.1111/ijlh.13716, 3 doi:10.1111/ijlh.13716 (međunarodna recenzija, pismo uredniku, znanstveni)
-
50.Higher red blood cell distribution width predicts thrombosis risk in primary and secondary myelofibrosis // Annals of hematology, 101 (2021), 6; 1355-1357 doi:10.1007/s00277-021-04724-4 (međunarodna recenzija, pismo uredniku, znanstveni)
